Cash Flow Statement (Annual)
LOGL / Legend Oil and Gas, Ltd Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Cash Flows From Operating Activities|
|Net Income Loss||-158||-6,049||-9,281||-12,331||-2,356||-14,990||-7,085|
|Adjustments To Reconcile Net Loss To Cash Flows From Operating Activities|
|Share Based Compensation||-||1,465||1,386||1,468||811||0||11|
|Asset Retirement Obligation Accretion Expense||-||15||59||63||16||28||44|
|Share Based Goods And Nonemployee Services Transaction Cash Flow Effects||-||20||152||-||-||-||-|
|Business Combination Acquisition Related Costs||-||1,404||4,147||0||-||-||-|
|Depletion Depreciation Amortization And Impairment||-||2,052||2,115||8,207||-||-||-|
|Changes In Operating Assets And Liabilities|
|Increase Decrease In Accounts Receivable||11||377||-94||27||-257||-952||51|
|Increase Decrease In Prepaid Deferred Expense And Other Assets||23||71||15||-3||-48||243||-|
|Increase Decrease In Accounts Payable||12||485||1,067||275||-90||218||-292|
|Net Cash Provided By Used In Operating Activities||-175||-1,057||-532||-1,416||-1,823||-2,536||-3,221|
|Cash Flows From Investing Activities|
|Payments To Explore And Develop Oil And Gas Properties||-||253||508||930||1,200||856||-|
|Net Cash Provided By Used In Investing Activities||-629||-9,043||1,608||1,130||-984||-758||-570|
|Cash Flows From Financing Activities|
|Proceeds From Repayments Of Notes Payable||-||5,094||-1,392||-1,310||-||-||-|
|Net Cash Provided By Used In Financing Activities||904||10,094||-970||-108||3,445||3,056||3,488|
|Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Change||-||-6||106||-394||-||-||-|
|Effect Of Exchange Rate On Cash And Cash Equivalents||-||-42||-146||446||-||-||-|
|Cash And Cash Equivalents Period Increase Decrease||100||-48||-40||51||638||-238||-302|
|Cash And Cash Equivalents At Carrying Value||-||53||13||64||702||464||161|
|Supplemental Disclosures Of Cash Flow Information|
|Cash Paid During The Year For|
Peers - Drilling Oil and Gas Wells (1381)
AMAZ / Amazing Energy Oil & Gas Co.
BKRP / Black Rock Petroleum Company
ERINQ / Erin Energy Corp
FTMR / Fortem Resources Inc.
HEROQ / HERCULES OFFSHORE INC Common Stock
HEVI / Heavy Earth Resources, Inc.
HKEB / HK eBus Corporation
IFNY / Infinity Energy Resources, Inc.
NOBGF / Noble Group Ltd.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET